La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CK Hutchison Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CK Hutchison Holdings..

CK Hutchison Holdings (OTC:CKHUY) Azioni, Catena delle Opzioni

CK Hutchison Holdings, or CKH, is a Hong Kong headquartered conglomerate with key businesses in ports, retail, infrastructure, and telecommunications. The company was created in 2015 to house the merged assets of Cheung Kong Holdings and Hutchison Whampoa as the group sought to flatten out and simplify its original holding structure. CKH contains most of the businesses previously housed in Hutchison Whampoa, minus the property assets, which were spun off into their own listing, CK Asset Holdings. Telecommunications and infrastructure activities now make up the largest share of EBITDA, at around 53%.

CK HUTCH HLD LTD UNSP/ADR by CK Hutchison Holdings LTD

CK Hutchison Holdings Ltd

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $15.853 million which beat the analyst consensus estimate of $15.850 million by 0.02 percent. This is a 2.76 percent decrease over sales of $16.303 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

SOPH

Sophia Genetics Q3 2024 GAAP EPS $(0.28) Misses $(0.22) Estimate, Sales $15.853M Beat $15.850M Estimate

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Downgrades

Price Target

Analyst Ratings

CGNX

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Buybacks

Emerson Reveals Increased Return of Capital To Shareholders With Plans To Repurchase Approximately $2B Of Shares In FY25; Expecting $1B In Fiscal Q1

Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) released its Q3 earnings on Thursday, October 24, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Competitors' Recent Earnings Updates</h3>
It's important to consider Boyd Gaming's numbers in relation to how its competitors, like PENN Entertainment, Golden Entertainment, and Inspired Entertainment, have been performing.
<ul>
<li>PENN Entertainment announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.26, PENN Entertainment's actual EPS was $-0.18, reflecting a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
Here's a comparison table presenting estimated and announced revenue figures for Boyd Gaming's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Boyd Gaming Earnings Review: Q3 Summary

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

NXPI

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Upgrades

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

CK Hutchison Holdings Ltd: A 'China Discount' Is Not Warranted

CK Asset Holdings: It's Not About Hong Kong Anymore, Management's Focus Seems To Have Shifted

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
U.S. stock indices have reached new highs, driven by strong corporate earnings, especially in technology. Meanwhile, many non-U.S. stocks have lagged so far in 2024. For instance, the <a href="https://www.ishares.com/us/products/239600/">iShares MSCI ACWI ETF</a> (NASDAQ:<a href="https://investorplace.com/stock-quotes/acwi-stock-quote/">ACWI</a>), heavily weighted towards U.S. equities, has gained 15% year-to-date (YTD), while the <a href="https://www.ishares.com/us/products/239594/">iShares MSCI ACWI ex U.S. ETF</a> (NASDAQ:<a href="https://investorplace.com/stock-quotes/acwx-stock-quote/">ACWX</a>), focusing on global stocks excluding the U.S., returned 10%.



Looking ahead, potential headwinds such as mixed economic indicators, Federal Reserve policy shifts and geopolitical tensions could mean short-term glitches on Wall Street. The upcoming U.S. presidential election also adds another layer of uncertainty. Thus, having exposure to international stocks could help mitigate risks from U.S. market volatility.



With that in mind, here are two global stocks and an exchange-traded fund (ETF) that provide exposure to international equities for portfolio diversification by offering opportunities in expanding economies and emerging markets.



<h2>GigaCloud Technology (GCT)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/05/worldtech.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/worldtech-300x169.png" alt=""></a>First on our list of global stocks is GigaCloud Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/gct-stock-quote/">GCT</a>). The Hong Kong-based company operates a global business-to-business (B2B) marketplace for big and bulky products. Launched in January 2019, GCT started with furniture and expanded into home appliances, fitness equipment and pet products.



In May, GCT reported stellar <a href="https://investors.gigacloudtech.com/news-releases/news-release-details/gigacloud-technology-inc-announces-first-quarter-ended-march-31">first-quarter 2024 results.</a> Revenues hit a record $251.1 million, up 96.5% from last year. Adjusted diluted EPS jumped 71.4% year-over-year (YOY) to 84 cents. The company also saw a 124.7% surge in gross profit and increased gross margin to 26.5%, demonstrating improved efficiency and profitability.



GigaCloud has been rapidly growing, with more active sellers, buyers and higher spending per buyer. A 64% YOY increase in its Marketplace Gross Merchandise Value (GMV) highlights the company&rsquo;s strong B2B e-commerce position and growth potential. Strategic investments in fulfillment infrastructure, like the recent expansion of its global network <a href="https://investors.gigacloudtech.com/news-releases/news-release-details/gigacloud-technology-inc-expands-global-fulfillment-network">to over 10 million square feet,</a> enhance its capacity. The new <a href="https://investors.gigacloudtech.com/news-releases/news-release-details/gigacloud-technology-inc-launches-new-service">Branding-as-a-Service</a> (BaaS) program also strengthens seller competitiveness and boosts user engagement.



So far in 2024, GTC stock has gained 63%. Yet, it is still reasonably valued at <a href="https://finance.yahoo.com/quote/GCT/key-statistics/">10 times forward earnings</a> and 1.5 times sales. Analysts are bullish on GCT stock, with a <a href="https://edition.cnn.com/markets/stocks/GCT">12-month median price forecast</a> of $46.00, indicating over a 51% potential upside.



<h2>iShares International Select Dividend ETF (IDV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/dividend-stocks1600-4-300x169.png" alt="Notebook with Tools and Notes about Dividends. Dividend stocks. Safe Dividend Stocks"><div>Source: Michail Petrov / Shutterstock.com</div></div>For broader global stock exposure with lower individual stock risks, an ETF like the <a href="https://www.ishares.com/us/products/239499/ishares-international-select-dividend-etf">iShares International Select Dividend ETF</a> (BATS:<a href="https://investorplace.com/stock-quotes/idv-stock-quote/">IDV</a>) could be a viable option for some of our readers. This ETF focuses on high dividend-paying equities in non-U.S. developed markets. It provides stable income in low-rate environments while mitigating risks from U.S. market fluctuations.



IDV was launched in June 2007. Currently, it holds 101 stocks, with the top 10 holdings comprising 30% of its nearly $4.2 billion net assets. The fund has significant allocations to financials (31.3%), utilities (16.4%) and communication sectors (11.5%).



Geographically, the U.K. (23.8%) leads, followed by Italy (10.2%), Spain (8.7%), France (7.8%) and Canada (7.5%). Among the top holdings are the U.K.-based telecommunications group BT (OTCMKTS:<a href="https://investorplace.com/stock-quotes/btgof-stock-quote/">BTGOF</a>) and financial heavyweight NatWest (NYSE:<a href="https://investorplace.com/stock-quotes/nwg-stock-quote/">NWG</a>), Hong Kong-based CK Hutchison (OTCMKTS:<a href="https://investorplace.com/stock-quotes/ckhuy-stock-quote/">CKHUY</a>) and Canadian company Manulife Financial (NYSE:<a href="https://investorplace.com/stock-quotes/mfc-stock-quote/">MFC</a>).



So far in 2024, IDV has returned over 4%, boasting a generous 6.7% dividend yield. Meanwhile, investors should note the expense ratio of 0.51%. Currently, IDV&rsquo;s trailing price-to-earnings (P/E) and price-to-book (P/B) ratios stand at 9x and 0.96x, respectively. With a diverse portfolio of high-quality international companies and a strong track record, IDV presents a reliable hedge against domestic market volatility.



<h2>Novartis (NVDS)</h2>



<a href="https://investorplace.com/wp-content/uploads/2020/01/novartis.jpg"><img width="300" height="225" src="https://investorplace.com/wp-content/uploads/2020/01/novartis-300x225.jpg" alt="A photo of a large building with a Novartis sign on it"></a>Concluding today&rsquo;s discussion on global stocks, we explore Novartis (NYSE:<a href="https://investorplace.com/stock-quotes/nvs-stock-quote/">NVS</a>). The Swiss multinational pharmaceutical corporation is known for its robust market position, diversified product portfolio and significant investments in research and development. That makes Novartis a stable global stock option with growth potential amid market choppiness.



<a href="https://www.novartis.com/sites/novartiscom/files/2024-04-interim-financial-report-en.pdf">In the first quarter of 2024,</a> Novartis reported impressive financial results. Revenue grew to $11.9 billion, up 11% YOY in constant currency terms. Core EPS also rose by 16.9% YOY to $1.80, driven by higher net sales and core operating net income. The company raised its full-year 2024 sales guidance to high single to low double-digit growth, reflecting strong performance across key brands and geographies.



Novartis is pushing forward with its pipeline, highlighted by promising Phase III results for remibrutinib in treating chronic spontaneous urticaria. Its cancer treatments, including <a href="https://www.novartis.com/news/novartis-confirms-plans-file-pluvicto-pre-taxane-label-expansion-h2-2024-based-latest-data-from-phase-iii-psmafore-study">Pluvicto</a>, <a href="https://www.novartis.com/news/media-releases/latest-analysis-novartis-natalee-study-shows-kisqali-reduces-risk-cancer-recurrence-early-breast-cancer-patients-high-risk-node-negative-disease">Kisqali</a> and <a href="https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml">Scemblix</a> are expanding their applications. Furthermore, <a href="https://seekingalpha.com/article/4702905-morphosys-stock-mor-novartis-deal-all-but-done?source=url_first_level%253Anews%257Csection%253Anews_more_on%257Csection_asset%253Aline_1%257Cbutton%253Alink">the pending acquisition</a> of MorphoSys (NASDAQ:<a href="https://investorplace.com/stock-quotes/mor-stock-quote/">MOR</a>) is set to bolster its oncology portfolio, solidifying its strategic market position.



Since January, NVS stock has advanced almost 11% and offers a 3.4% dividend yield. The shares are trading at 15 times forward earnings and <a href="https://www.morningstar.com/stocks/xnys/nvs/quote">4.8 times sales.</a> Finally, analysts have a <a href="https://edition.cnn.com/markets/stocks/nvs">12-month median price target</a> of $116.00 for Novartis stock, a 3.8% upside potential from the current levels.



On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Tezcan Gecgil, PhD, began contributing to InvestorPlace in 2018. She brings over 20 years of experience in the U.S. and U.K. and has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Publicly, she has contributed to <a href="https://www.investing.com/">investing.com</a> and the U.K. website of <a href="https://www.fool.com/">The Motley Fool.</a></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-global-stocks-to-buy-to-escape-the-volatility-on-wall-street/">3 Global Stocks to Buy to Escape the Volatility on Wall Street</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

CK Hutchison Holdings

CK Hutchison Holdings (CKHUY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO